164
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Giant Lupus Vulgaris with Negative T-SPOT.TB, a Case Report and Literature Review

ORCID Icon & ORCID Icon
Pages 1119-1123 | Published online: 18 Jun 2022

References

  • Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous mycobacterial infections. Clin Microbiol Rev. 2018;32(1):e00069–18. doi:10.1128/CMR.00069-18
  • Arora K, Batra A, Dhanta A, Hazarika N. Lupus vulgaris in a mother and child. BMJ Case Rep. 2021;14(3):e240591. doi:10.1136/bcr-2020-240591
  • Walker SL, Lozewicz S, Sood R, Mann TA, Campalani E, Hubbard VG. Lupus vulgaris due to Mycobacterium bovis bacillus Calmette-Guérin (BCG) at the site of previous BCG vaccination. Clin Exp Dermatol. 2009;34(7):e213–5. doi:10.1111/j.1365-2230.2008.03057.x
  • Kogut M, Hadaschik E, Grabbe S, Andrulis M, Enk A, Hartschuh W. Granulomatous mycosis fungoides, a rare subtype of cutaneous T-cell lymphoma. JAAD Case Rep. 2015;1(5):298–302. doi:10.1016/j.jdcr.2015.05.010
  • Landau M, Srebrnik A, Brenner S. Leishmaniasis recidivans mimicking lupus vulgaris. Int J Dermatol. 1996;35(8):572–573. doi:10.1111/j.1365-4362.1996.tb03658.x
  • Sirka CS, Rout AN, Kumar P, Purkait S. Lupus vulgaris masquerading as tumorous growth. Indian J Dermatol Venereol Leprol. 2021;87(4):562–565. doi:10.25259/IJDVL_1008_20
  • Garg V, Shastri M, Nanda A. Lupus vulgaris uncovered by FNAC after a decade of clinical misdiagnosis as hemangioma. Indian J Pathol Microbiol. 2021;64(2):420–422. doi:10.4103/IJPM.IJPM_42_20
  • Sammain A, Jocher A, Bruckner-Tuderman L, Schempp CM. Lupus vulgaris–a case diagnosed more than 20 years after onset. J Dtsch Dermatol Ges. 2006;4(11):958–960. doi:10.1111/j.1610-0387.2006.06114.x
  • Kaul S, Jakhar D, Mehta S, Singal A. Cutaneous tuberculosis. Part II: complications, diagnostic workup, histopathological features, and treatment. J Am Acad Dermatol. 2022;8. DOI:10.1016/j.jaad.2021.12.064
  • Chen Y, Jiang H, Zhang W, et al. Diagnostic value of T-SPOT.TB test in cutaneous mycobacterial infections. Acta Derm Venereol. 2018;98(10):989–990. doi:10.2340/00015555-3011
  • Li K, Yang C, Jiang Z, et al. Quantitative investigation of factors relevant to the T cell spot test for tuberculosis infection in active tuberculosis. BMC Infect Dis. 2019;19(1):673. doi:10.1186/s12879-019-4310-y
  • Pan L, Jia H, Liu F, et al. Risk factors for false-negative T-SPOT.TB assay results in patients with pulmonary and extra-pulmonary TB. J Infect. 2015;70(4):367–380. doi:10.1016/j.jinf.2014.12.018
  • Nguyen DT, Teeter LD, Graves J, Graviss EA. Characteristics associated with negative interferon-γ release assay results in culture-confirmed tuberculosis patients, Texas, USA, 2013–2015. Emerg Infect Dis. 2018;24(3):534–540. doi:10.3201/eid2403.171633
  • Hang NT, Lien LT, Kobayashi N, et al. Analysis of factors lowering sensitivity of interferon-γ release assay for tuberculosis. PLoS One. 2011;6(8):e23806. doi:10.1371/journal.pone.0023806
  • Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest. 2008;133(5):1196–1202. doi:10.1378/chest.07-1995
  • Ramam M, Ramesh V. Trial of antitubercular therapy in the diagnosis of cutaneous tuberculosis. Am J Dermatopathol. 2010;32(3):316. doi:10.1097/DAD.0b013e3181c6ed81
  • Santesteban R, Bonaut B, Córdoba A, Yanguas I. Paradoxical reaction to antituberculosis therapy in a patient with lupus vulgaris. Actas Dermosifiliogr. 2015;106(2):e7–e12. doi:10.1016/j.ad.2014.05.003